Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 6, 2010, Pages 1220-1227

  Majak, Paweł ^a   Rychlik, Błazej ^b   Pułaski, Łukasz ^b,c   Błauz, Andrzej ^b   Agnieszka, Brzozowska ^a   Bobrowska Korzeniowska, Monika ^a   Kuna, Piotr ^a   Stelmach, Iwona ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

asthma; Immunotherapy; montelukast

Indexed keywords

BUDESONIDE; CORTICOSTEROID; MONTELUKAST; PLACEBO;

ARTICLE; ASTHMA; BEDTIME DOSAGE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SYMPTOM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ACETATES; ADMINISTRATION, INHALATION; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BUDESONIDE; CHEMOTHERAPY, ADJUVANT; CHILD; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE ACTIVATION; PYROGLYPHIDAE; QUINOLINES; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 77952744385     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.02.034     Document Type: Article

References (26)

1. Larché M., Akdis C.A., and Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6 (2006) 761-771
2. Akdis M., and Akdis C.A. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119 (2007) 780-791
3. Bohle B., Kinaciyan T., Gerstmayr M., Radakovics A., Jahn-Schmid B., and Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 120 (2007) 707-713
4. Meiler F., Zumkehr J., Klunker S., Ruckert B., Akdis C.A., and Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 205 (2008) 2887-2898
5. Nagato T., Kobayashi H., Yanai M., Sato K., Aoki N., Oikawa K., et al. Functional analysis of birch pollen allergen Bet v 1-specific regulatory T cells. J Immunol 178 (2007) 1189-1198
6. Jutel M., Akdis M., Budak F., Aebischer-Casaulta C., Wrzyszcz M., Blaser K., et al. IL- 10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33 (2003) 1205-1214
7. Radulovic S., Jacobson M.R., Durham S.R., and Nouri-Aria K.T. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 121 (2008) 1467-1472
8. Stelmach I., Jerzynska J., and Kuna P. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clin Exp Allergy 32 (2002) 264-269
9. Stelmach I., Majak P., Jerzynska J., and Kuna P. The effect of treatment with montelukast on in vitro interleukin-10 production of mononuclear cells of children with asthma. Clin Exp Allergy 35 (2005) 213-220
10. Woszczek G., Chen L.Y., Nagineni S., and Shelhamer J.H. IL-10 inhibits cysteinyl leukotriene-induced activation of human monocytes and monocyte-derived dendritic cells. J Immunol 180 (2008) 7597-7603
11. Wöhrl S., Gamper S., Hemmer W., Heinze G., Stingl G., and Kinaciyan T. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 144 (2007) 137-142
12. Stelmach I., Bobrowska-Korzeniowska M., Majak P., Stelmach W., and Kuna P. The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. Pulm Pharmacol Ther 18 (2005) 374-380
13. Maestrelli P., Zanolla L., Pozzan M., Fabbri L.M., and Regione Veneto Study Group on the "Effect of immunotherapy in allergic asthma". Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 113 (2004) 643-649
14. Stelmach I., Grzelewski T., Majak P., Jerzynska J., Stelmach W., and Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 121 (2008) 383-389
15. Pham-Thi N., Scheinmann P., Fadel R., Combebias A., and Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite avoidance measures. Pediatr Allergy Immunol 18 (2007) 47-57
16. Riccioni G., Di Stefano F., De Benedictis M., Verna N., Cavallucci E., Paolini F., et al. Seasonal variability of nonspecific bronchial responsiveness in asthmatic patients with allergy to house dust mites. Allergy Asthma Proc 22 (2001) 5-9
17. Global Strategy for Asthma Management and Prevention NIH publication no. 02-3659. Updated 2004 from the 2003 document. Available at: http://www.ginasthma.org/Guidelineitem.asp?l1=2&l2=1&intId=987). Accessed November 25, 2009.
18. Blumberga G., Groes L., Haugaard L., and Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 61 (2006) 843-848
19. Chen H., Qin J., Wei P., Zhang J., Li Q., Fu L., et al. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells. Prostaglandins Leukot Essent Fatty Acids 80 (2009) 195-200
20. Perng D.W., Wu Y.C., Chang K.T., Wu M.T., Chiou Y.C., Su K.C., et al. Leukotriene C4 induces TGF-beta1 production in airway epithelium via p38 kinase pathway. Am J Respir Cell Mol Biol 34 (2006) 101-107
21. Marie J.C., Letterio J.J., Gavin M., and Rudensky A.Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201 (2005) 1061-1067
22. Saeki S., Matsuse H., Kondo Y., Machida I., Kawano T., Tomari S., et al. Effects of antiasthmatic agents on the functions of peripheral blood monocyte-derived dendritic cells from atopic patients. J Allergy Clin Immunol 114 (2004) 538-544
23. Perry T.T., Corren J., Philip G., Kim E.H., Conover-Walker M.K., Malice M.P., et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol 93 (2004) 431-438
24. Bisgaard H., Zielen S., Garcia-Garcia M.L., Johnston S.L., Gilles L., Menten J., et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 171 (2005) 315-322
25. Johnston N.W., Mandhane P.J., Dai J., Duncan J.M., Greene J.M., Lambert K., et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 120 (2007) 702-712
26. Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., and Togias A. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 86 (2008) 8-160